|Table of Contents|

Correlation and clinical roles of Oct4 and EGFR in right-sided colon cancer tissue

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 01
Page:
94-97
Research Field:
Publishing date:

Info

Title:
Correlation and clinical roles of Oct4 and EGFR in right-sided colon cancer tissue
Author(s):
CHENG Jie1; SHI Chuntao1; CHEN Chaobo1; HAN Wei2; WANG Qinghua3
1.Department of General Surgery,Wuxi Xishan People's Hospital,Jiangsu Wuxi 214000,China;2.Department of General Surgery;3.Gastroenterology Department,Kunshan Hospital Affiliated to Jiangsu University,Jiangsu Kunshan 215300,China.
Keywords:
Oct4; EGFR; right-side colon cancer; correlation
PACS:
R735.3+5
DOI:
10.3969/j.issn.1672-4992.2022.01.020
Abstract:
Objective:To investigate the correlation and clinical value of Oct4 and EGFR in right-sided colon cancer.Methods:Expressions of Oct4 and EGFR in 120 cases of right-sided colon cancer were detected by immunohistochemistry and the relationship of pathological parameters were analyzed.The correlation between Oct4 and EGFR was confirmed through immunohistochemistry and the GEPIA database.Results:Immunohistochemical staining showed that Oct4 expression was positively correlated with histological grade,lymph node metastasis and TNM stage(P＜0.05),while EGFR was positively correlated with tumor diameter,histological grade and TNM stage(P＜0.01).According to the immunohistochemical score,the EGFR positive expression rate was 50.0%(26/52) in the positive expression of Oct4,while the EGFR positive expression rate was only 29.41%(20/68) in the negative expression of Oct4.Combined with the analysis of the GEPIA database,it was confirmed that Oct4 was positively correlated with EGFR.In addition,26 cases both with Oct4 and EGFR positive in were positively correlated with tumor diameter,histological grade,lymph node metastasis and TNM stage(P＜0.05).Conclusion:There is a positive correlation between Oct4 and EGFR in the right-side colon cancer.The combined detection of Oct4 and EGFR could make up the deficiency of clinical pathology diagnosis and provide a new theoretical basis for the exploration of targeted therapy for the right-side colon cancer.

References:

[1] 林锦源,杨建伟,高炜,等.不同原发部位结肠癌根治术后辅助化疗的预后和安全性比较［J］.实用肿瘤杂志,2019,34(06):486-491. LIN JY,YANG JW,GAO W,et al.Comparison of prognosis and safety of adjuvant chemotherapy after radical resection of different primary sites of colon cancer［J］.Journal of Practical Oncology,2019,34(06):486-491.
[2] 邱萌,陈烨.结肠癌围手术期治疗进展［J］.中华结直肠疾病电子杂志,2019,8(05):447-453. QIU M,CHEN Y.Recent advances in neoadjuvant and adjuvant treatment of colon cancer［J］.Chinese Journal of Colorectal Diseases,2019,8(05):447-453.
[3] 程杰,史春桃,陈超波,等.Oct4蛋白在左右半结肠癌中表达的比较及预后分析［J］.中国肿瘤临床,2017,44(18):909-914. CHENG J,SHI CT,CHEN CB,et al.Expression of Oct4 and its prognostic role in left-and right-side colon cancer［J］. Chinese Journal of Clinical Oncology,2017,44(18):909-914.
[4] 张子怡,林泉任,叶春雨,等.结肠癌干细胞标志物和信号通路的研究进展［J］.生命科学,2019,31(08):802-811. ZHANG ZY,LIN QR,YE CY,et al.Advances in the study of stem cell markers and signaling pathways in colon cancer［J］.Life Science,2019,31(08):802-811.
[5] 王璐,孙小虎,白静慧,等.Trem-1和EGFR在结肠癌组织中表达及意义［J］.中西医结合心血管病电子杂志,2018,6(31):3-6. WANG L,SUN XH,BAI JH,et al.Expression and significance of Trem-1 and EGFR in colorecal carcinoma［J］.Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine(Electronic),2018,6(31):3-6.
[6]李彬.Oct4在非小细胞肺癌中的表达及对吉非替尼耐药性的影响［D］.济南：山东大学,2017. LI B.Expression and molecular mechanism of Oct4 in the resistance of non-small cell lung cancer to gefitinib［D］.Jinan:Shandong University,2017.
[7] 胡雪娥,史丽芸,孟春玲,等.左右半结肠癌生物学特征的差异及常用病理标志的临床意义［J］.中国临床研究,2018,31(12):1669-1673. HU XE,SHI LY,MENG CL,et al.Differences in biological characteristics of left-and right-sided colon cancers and clinical significance of common pathological markers［J］.Chinese Journal of Clinical Research,2018,31(12):1669-1673.
[8] 邓婷,巴一.左右半结肠癌差异性研究进展［J］.中国肿瘤临床,2015,42(13):684-688. DENG T,BA Y.Research progress on differences between left-and right-sided colon cancers［J］.Chinese Journal of Clinical Oncology,2015,42(13):684-688.
[9] 李伶俐,朱蓉,陈小燕,等.Oct4与结肠癌发生发展关系的研究进展［J］.世界华人消化杂志,2015,23(33):5325-5332. LI LL,ZHU R,CHEN XY,et al.Research progress of Oct4 and development of colon cancer［J］.World Chinese Digestion Journal,2015,23(33):5325-5332.
[10] 胡俊杰,熊治国.左、右半结肠癌“两种疾病论”的研究进展［J］.中华结直肠疾病电子杂志,2016,5(05):380-385. HU JJ,XIONG ZG.The research progress of two diseases theory of left and right colon cancer［J］.Chinese Electronic Journal of Colorectal Diseases,2016,5(05):380-385.
[11]刘锐锋,魏世鸿,罗宏涛,等.埃克替尼联合胸部放疗与单独埃克替尼比较治疗EGFR突变阳性Ⅲ/Ⅳ期NSCLC的临床对照研究［J］.中国肿瘤,2020,29(06):463-475. LIU RF,WEI SH,LUO HT,et al.Icotinib combined with thoracic radiotherapy versus icotinib alone in treatment of EGFR mutation positive stage Ⅲ/Ⅳ NSCLC:A retrospective clinical controlled atudy［J］.Bulletin of Chinese Cancer,2020,29(06):463-475.
[12] LEONETTI A,SHARMA S,MINARI R,et al.Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer［J］.Br J Cancer,2019,121(9):725-737.
[13] WU SG,SHI JY.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer［J］.Mol Cancer,2018,17(1):38.
[14] WANG QH,ZHANG M,SHI CT,et al.High Oct4 predicted worse prognosis of right-sided colon cancer patients［J］.Future Oncol,2018,14(22):2279-2291.
[15] 李文生,郑幼伟,孙君军,等.结肠癌组织表皮生长因子受体的表达及其临床意义［J］.中华实验外科杂志,2019,36(07):1299-1301. LI WS,ZHENG YW,SUN JJ,et al.Expression of epidermal growth factor receptor in colon cancer with different pathological characteristics and its clinical significance［J］.Chinese Journal of Experimental Surgery,2019,36(07):1299-1301.
[16] LIU X,LUKOWSKI JK,FLINDERS C,et al.MALDI-MSI of immunotherapy:Mapping the EGFR-targeting antibody cetuximab in 3D colon-cancer cell cultures［J］.Anal Chem,2018,90(24):14156-14164.

Memo

Memo:
-
Last Update: 2021-12-02